• 1
    Daley D, Lewis S, Platzer P, et al. Identification of susceptibility genes for cancer in a genome-wide scan: results from the colon neoplasia sibling study. Am J Hum Genet 2008; 82: 72336.
  • 2
    Fahy B, Bold RJ. Epidemiology and molecular genetics of colorectal cancer. Surg Oncol 1998; 7: 11523.
  • 3
    Saito H. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J Med Screen 2006; 13: S6S7.
  • 4
    Ortega J, Vigil CE, Chodkiewicz C. Current progress in targeted therapy for colorectal cancer. Cancer Control 2010; 17: 715.
  • 5
    Sheth RA, Mahmood U. Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2010; 299: G80720.
  • 6
    Kelly K, Alencar H, Funovics M, et al. Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res 2004; 64: 624751.
  • 7
    Hsiung PL, Hardy J, Friedland S, et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 2008; 14: 4548.
  • 8
    Yuan M, Itzkowitz SH, Boland CR, et al. Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry. Cancer Res 1986; 46: 48417.
  • 9
    Rosenberg WM, Prince C, Kaklamanis L, et al. Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet 1995; 345: 12059.
  • 10
    Singh R, Campbell BJ, Yu LG, et al. Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. Glycobiology 2001; 11: 58792.
  • 11
    Yuan M, Itkowitz SH, Boland CR, et al. Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry. Cancer Res 1986; 46: 48417.
  • 12
    Bray J, MacLean GD, Dusel FJ, et al. Decreased levels of circulating lytic anti-T in The serum of patients with metastatic gastrointestinal cancer: a correlation with disease burden. Clin Exp Immunol 1982; 47: 17682.
  • 13
    Ryder SD, Smith JA, Rhodes JM. Peanut lectin: a mitogen for normal human colonic epithelium and human HT29 colorectal cancer cells. J Natl Cancer Inst 1992; 84: 14106.
  • 14
    Boland CR, Roberts JA. Quantitation of lectin binding sites in human colon mucins by use of peanut and wheat germ agglutinins. J Histochem Cytochem 1988; 36: 13057.
  • 15
    Boland CR, Montgomery CK, Kim YS. A cancer-associated mucin alteration in benign colonic polyps. Gastroenterology 1982; 82: 66472.
  • 16
    Rhodes JM, Black RR, Savage A. Glycoprotein abnormalities in colonic carcinomata, adenomata, and hyperplastic polyps shown by lectin peroxidase histochemistry. J Clin Pathol 1986; 39: 13314.
  • 17
    McEwan AJ, MacLean GD, Hooper HR, et al. MAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with 99Tcm and with 111In. Nucl Med Commun 1992; 13: 1119.
  • 18
    Sakuma S, Sudo R, Suzuki N, et al. Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. J Control Release 2002; 81: 28190.
  • 19
    Sakuma S, Hayashi M, Akashi M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev 2001; 47: 2137.
  • 20
    Sakuma S, Sudo R, Suzuki N, et al. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int J Pharm 1999; 177: 16172.
  • 21
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 4028.
  • 22
    Steuden I, Duk M, Czerwinski M, et al. The monoclonal antibody, anti-asialoglycophorin from human erythrocytes, specific for -D-Gal-I-3-c -D-GalNAc-chains (Thomsen-Friedenreich receptors). Glycoconjugate J 1985; 2: 30314.
  • 23
    Cao Y, Karsten UR, Liebrich W, et al. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer 1995; 76: 17008.
  • 24
    Nemoto-Sasaki Y, Mitsuki M, Morimoto-Tomita M, et al. Correlation between the sialylation of cell surface Thomsen-Friedenreich antigen and the metastatic potential of colon carcinoma cells in a mouse model. Glycoconjugate J 2001; 18: 895906.
  • 25
    Itzkowitz SH, Yuan M, Montgomery CK, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989; 49: 197204.
  • 26
    Brockhausen I, Schutzbach J, Kuhns W. Glycoproteins and their relationship to human disease. Acta Anat (Basel) 1998; 161: 3678.
  • 27
    Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198206.
  • 28
    Springer GF, Desai PR, Wise W, et al. Pancarcinoma T and Tn epitopes: autoimmunogens and diagnostic markers that reveal incipient carcinomas and help establish prognosis. Immunol Ser 1990; 53: 587612.
  • 29
    Moriyama H, Nakano H, Igawa M, et al. T antigen expression in benign hyperplasia and adenocarcinoma of the prostate. Urol Int 1987; 42: 1203.
  • 30
    Wolf MF, Ludwig A, Fritz P, et al. Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients. Tumour Biol 1988; 9: 1904.
  • 31
    Xu Y, Sette A, Sidney J, et al. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol Cell Biol 2005; 83: 4408.
  • 32
    Xu Y, Gendler SJ, Franco A. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 2004; 199: 70716.
  • 33
    Jeschke U, Walzel H, Mylonas I, et al. The human endometrium expresses the glycoprotein mucin-1 and shows positive correlation for Thomsen-Friedenreich epitope expression and galectin-1 binding. J Histochem Cytochem 2009; 57: 87181.